(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.34%) $0.935
(0.55%) $11.01
(0.18%) $0.801
(0.00%) $92.17
2 days till quarter result
(bmo 2024-04-30)
Expected move: +/- 2.39%
Live Chart Being Loaded With Signals
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies...
Stats | |
---|---|
Šios dienos apimtis | 19 150.00 |
Vidutinė apimtis | 60 538.00 |
Rinkos kapitalizacija | 232.56M |
EPS | £0 ( 2023-11-07 ) |
Kita pelno data | ( £0 ) 2024-04-30 |
Last Dividend | £14.20 ( 2023-07-27 ) |
Next Dividend | £0 ( N/A ) |
P/E | 36.24 |
ATR14 | £2.02 (0.33%) |
Tūris Koreliacija
International Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
International Koreliacija - Valiuta/Žaliavos
International Finansinės ataskaitos
Annual | 2023 |
Pajamos: | £8.49M |
Bruto pelnas: | £8.49M (100.00 %) |
EPS: | £0.170 |
FY | 2023 |
Pajamos: | £8.49M |
Bruto pelnas: | £8.49M (100.00 %) |
EPS: | £0.170 |
FY | 2022 |
Pajamos: | £-21.10M |
Bruto pelnas: | £-21.10M (100.00 %) |
EPS: | £-0.550 |
FY | 2021 |
Pajamos: | £29.12M |
Bruto pelnas: | £0.00 (0.00 %) |
EPS: | £0.725 |
Financial Reports:
No articles found.
International Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£15.70 (N/A) |
£14.00 (N/A) |
£0 (N/A) |
£0 (N/A) |
£14.20 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £1.000 | 1995-11-13 |
Last Dividend | £14.20 | 2023-07-27 |
Next Dividend | £0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | £191.80 | -- |
Avg. Dividend % Per Year | 2.11% | -- |
Score | 4.55 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.51 | |
Div. Directional Score | 8.52 | -- |
Year | Amount | Yield |
---|---|---|
1995 | £0 | 0.00% |
1996 | £0 | 0.00% |
1997 | £0 | 0.00% |
1998 | £0 | 0.00% |
1999 | £0 | 0.00% |
2000 | £0 | 0.00% |
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £41.00 | 7.36% |
2019 | £26.40 | 4.63% |
2020 | £26.60 | 4.28% |
2021 | £29.90 | 3.70% |
2022 | £29.70 | 4.04% |
2023 | £14.20 | 1.97% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
THRG.L | Dividend Knight | 2023-08-03 | Semi-Annually | 52 | 1.02% | |
LMP.L | Dividend Knight | 2023-08-31 | Quarterly | 17 | 2.52% | |
CMCL.L | Dividend Knight | 2023-07-13 | Quarterly | 12 | 3.19% | |
RIII.L | Dividend Knight | 2023-08-24 | Semi-Annually | 44 | 1.13% | |
HCFT.L | Dividend Knight | 2023-09-21 | Semi-Annually | 32 | 4.67% | |
ASY.L | Dividend Knight | 2023-05-25 | Semi-Annually | 32 | 2.95% | |
ULVR.L | Dividend King | 2023-08-03 | Quarterly | 33 | 2.11% | |
MINI.L | No Dividend Player | 2023-09-28 | Annually | 9 | 0.05% | |
DATA.L | Dividend King | 2023-09-07 | Semi-Annually | 9 | 7.09% | |
SEQI.L | Dividend Knight | 2023-07-27 | Quarterly | 10 | 3.85% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.651 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0223 | 1.200 | 9.26 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0241 | 1.500 | -0.844 | -1.265 | [0.1 - 1] |
payoutRatioTTM | 1.674 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 19.01 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 19.01 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0.213 | -1.500 | 6.45 | -9.67 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.676 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.676 | 2.00 | 9.66 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.240 | -1.500 | 9.04 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.629 | 1.000 | 10.00 | 10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.420 | 1.000 | 8.78 | 8.78 | [0.2 - 2] |
assetTurnoverTTM | 0.0343 | 0.800 | -3.10 | -2.48 | [0.5 - 2] |
Total Score | 10.54 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 36.50 | 1.000 | 6.41 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0241 | 2.50 | -0.542 | -1.265 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.676 | 2.00 | 9.77 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.56 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.676 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.674 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 27.88 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 2.61 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 6.51 |
International
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of these companies to strategic buyers including major pharmaceutical companies or, in some cases, and through a flotation.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.